Skip to content

Assessment of Autogenous Dentin Graft in Treatment of Infra-bony Defect

Clinical and Radiographic Assessment of Autogenous Dentin Nanoparticles in Treatment of Stage III Periodontitis: A Split-Mouth Clinical Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05258006
Enrollment
20
Registered
2022-02-25
Start date
2021-01-01
Completion date
2022-01-01
Last updated
2022-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis (Stage 3)

Brief summary

The aim of the present study was to evaluate the effect of demineralized autogenous dentine on treatment of infrabony defects.

Detailed description

In this study, the investigators tested the effect of demineralized autogenous dentine as a bone graft in treatment of stage III periodontitis in term of probing pocket depth reduction, mean gain in clinical attachment level, and bone gain in defect sites.

Interventions

PROCEDUREAutogenous demineralized dentin nanoparticles

Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect

Sponsors

October 6 University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
16 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Patients with good systemic health and no contraindication for periodontal surgery. * Patients who are able to maintain good oral hygiene. * Gingival thickness for the site selected should be ≥1mm. * Probing depth of ≥ 6mm. * Patient has at least one hopeless teeth

Exclusion criteria

* Active infectious diseases (hepatitis, tubercu¬losis, HIV, etc….). * Medically compromised patients. * Smokers and alcoholic abusers * People who suffer from any systemic disease that affect the periodontium. * Pregnant, postmenopausal women. * People who take anti-inflammatory drugs, anti¬biotics or vitamins within the previous 3 month. * People who use mouth washes regularly * Participants in other clinical trials.

Design outcomes

Primary

MeasureTime frameDescription
Vertical bone loss6 monthsvertical bone loss was measured from cementoenamel junction (CEJ) to the base of the bone defect in each site in group I & II.
Clinical attachment level6 monthsClinical attachment level was measured at baseline and 6 months
Probing pocket depth6 monthsProbing pocket depth was measured at baseline and 6 months
Bone gain6 monthsThe bone gain is calculated by: * Preoperative VBL (at baseline): measured as the distance from cementoenamel junction (CEJ) to the base of the bone defect. * Postoperative VBL (after 6 months) measured as the distance from cementoenamel junction (CEJ) to the base of the bone formation. * Postoperative bone fill (bone gain after 6 months) \[measured by subtracting the preoperative VBL from the postoperative VBL\].

Secondary

MeasureTime frameDescription
Plaque Index6 monthsplaque index was measured at baseline, 3, 6 months
Gingival index6 monthsGingival index was measured at baseline, 3, 6 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026